Domestic Anti-Cancer Drug Takes On the Global Drug King: A Crucial Competition About “8 More Months of Life”
Summary of Key Points
This news report discusses a dramatic and industry-defining event: at the 2026 World Lung Cancer Congress, the Chinese innovative pharmaceutical company CanSino Biologics announced significant data. Its independently developed PD-1/VEGF bispecific antibody drug, Yivoxi, achieved a remarkable victory in a head-to-head comparison with Keytruda (pembrolizumab) from Merck, which was once the global sales champion in the oncology field.
In simple terms, for patients with non-small cell lung cancer, using Yivoxi resulted in an average additional 8.2 months of survival compared to using Keytruda. More importantly, this was under fair conditions of “drug versus drug” (without any other medications being used). As the first drug in the world to successfully challenge Keytruda, Yivoxi demonstrates that the new generation of immunotherapy (bispecific antibodies) may surpass the effectiveness of the previous generation of cornerstone drugs (monoclonal antibodies). This is not just a victory for a single product but could also mark the beginning of a new “bispecific antibody era” in cancer immunotherapy.
---
Detailed Analysis
1. What is a “head-to-head” competition? Why is this so crucial?
Before a new drug is launched, it typically undergoes phase III clinical trials, which are like the final exams before obtaining a “degree.” Usually, new drugs are compared to a “placebo” or to existing drugs to prove their effectiveness. However, CanSino Biologics made a bold decision: to directly compete its new drug Yivoxi with Keytruda, the most powerful and mature anti-cancer drug in the world, among the same patient group.
This is like a duel between two skilled fighters, not about who has the most fancy moves, but about who can keep the patient alive longer.
- The Background: Keytruda (pembrolizumab) is a star product of Merck, having been the global “drug king” for many years, with sales reaching $31.68 billion in 2025. It is a representative of PD-1 monoclonal antibodies and has established the dominance of immunotherapy in oncology.
- The Rules: The study was “randomized, double-blind, and controlled,” meaning neither doctors nor patients knew which drug was being administered, eliminating psychological factors and human bias. The comparison was conducted in patients with positive PD-L1 expression, the group for which Keytruda is most effective, essentially fighting on the opponent’s home ground.
- The Results: The data showed that the median overall survival (OS) in the Yivoxi group was 30.8 months, compared to 22.6 months in the Keytruda group (30.8 - 8.2 = 22.6 months). An additional 8.2 months of survival is a huge improvement for patients with advanced cancer.
In plain terms: It’s like a football match where the new player (Yivoxi) not only didn’t lose but also scored 8 more goals than the team’s star player (Keytruda), and all this while the star player was in their best form.
2. How did Yivoxi win? The “dual-target” approach
The reason Yivoxi was able to defeat Keytruda lies in its different technical approach:
- Keytruda (PD-1 monoclonal antibody): It acts like a “key” that fits only one “lock” (the PD-1/PD-L1 pathway), unlocking the immune system to attack cancer cells. This is the current mainstream treatment method, but cancer cells are cunning and can evade this mechanism or use other pathways (such as angiogenesis) to sustain themselves.
- Yivoxi (PD-1/VEGF bispecific antibody): It’s like a “universal key” or a “combination punch” that targets two pathways:
1. PD-1: Unlocks the immune system’s brakes.
2. VEGF: Inhibits angiogenesis. Cancer cells grow rapidly and need a lot of blood vessels to feed them. Cutting off these blood vessels starves the cancer cells and also improves the tumor microenvironment, making it easier for immune cells to penetrate the tumor.
In plain terms:
- Keytruda: It’s like sending an army (immune cells) to battle, but the enemy (cancer cells) keeps strengthening their defenses and replenishing resources.
- Yivoxi: It not only sends the army but also cuts off the enemy’s supply lines (blood vessels) and removes their defenses (PD-L1). “Dual-targeting” means the effect is synergistic, with 1 + 1 > 2.
CanSino Biologics’ founder, Xia Yu, emphasized that Yivoxi is not just a mixture of two drugs; it’s a molecule with both functions, allowing for a stronger synergistic effect without any new safety issues.
3. The Impact on Keytruda’s status as the “drug king”: From “defending” to “being challenged”
Keytruda was the “drug king” because it pioneered the PD-1 monoclonal antibody era and proved effective in multiple cancer types. However, these results challenge its dominance:
- Breakthrough in efficacy: In the PD-L1 high-expression (TPS ≥ 50%) group, Keytruda’s median OS was 23.2 months, while Yivoxi’s group’s OS has not yet been published (indicating that more patients survived, with potential for further improvement). This shows that Yivoxi can perform even better in Keytruda’s strong area of expertise.
- Shaking the industry’s status: Keytruda’s dominance relied on its effectiveness in first-line non-small cell lung cancer. Now, a new drug has demonstrated that a “single drug” can surpass it in the same indication and patient group, shaking its status as the cornerstone drug.
- Changing market dynamics: Although Keytruda’s sales in 2025 were still $31.68 billion, the emergence of Yivoxi suggests a reshaping of the cancer immunotherapy market. Patients and doctors may prefer the more effective new drug, potentially squeezing Keytruda’s market share, especially in first-line treatments.
In plain terms: Keytruda was like the iPhone, dominating the high-end market for a long time. Now, Huawei (Yivoxi) has released a phone that performs better in the core aspect (survival time) and may be more affordable. Although the iPhone still has brand value and existing users, Huawei has a strong competitive edge in the growing market.
4. From “Chinese data” to “global recognition”: One last hurdle
While the data is impressive, it’s important to note that it comes from the Chinese population:
- Racial differences: Treatment outcomes may vary among different races and genetic backgrounds. Keytruda’s global approval is based on multi-center data. For Yivoxi to truly challenge Keytruda’s global status, it must prove its effectiveness in Western populations.
- International studies in progress: CanSino Biologics has started international multi-center phase III clinical trials (HARMONi-7/AK112-3007), which are crucial for global market entry.
- Regulatory approval: If the international data are equally impressive, Yivoxi could be approved by regulatory agencies like the FDA and EMA, opening up a huge market opportunity due to the large global lung cancer patient base.
In plain terms: It’s like a domestic car performing exceptionally well in China, but to become the global leader, it needs to prove its performance in different markets with different driving conditions.
5. Implications for investors and the industry: The bispecific antibody track enters a “golden age”
This event is not just a victory for CanSino Biologics but for the entire PD-1/VEGF bispecific antibody sector:
- Verification of the technology: Many companies were unsure whether bispecific antibodies were better than monoclonal antibodies or just a simple combination. Yivoxi’s data strongly demonstrates that bispecific antibodies can become the new cornerstone of immunotherapy, providing reassurance to companies developing them.
- Rise of domestic innovation: Chinese innovative drugs were often labeled as “me-too.” However, Yivoxi is a “first-in-class” or “best-in-class” challenger, marking a shift from following to leading in the field.
- Investment implications:
- Positive for CanSino Biologics: The competitiveness of its core product is confirmed, with higher global sales expectations.
- Positive for the bispecific antibody industry: The technology of other companies (such as Innovent and BeiGene) is validated, potentially increasing their valuations.
- Negative for traditional PD-1 monoclonal antibodies: The long-term growth of Keytruda and similar drugs may be limited, affecting the valuations of related multinational companies.
In plain terms: It’s like the electric vehicle industry, where traditional cars (monoclonal antibodies) were once dominant. Now, Tesla (Yivoxi) has proven that electric vehicles (bispecific antibodies) are more efficient and environmentally friendly, leading to a shift in the entire industry.
Conclusion
CanSino Biologics’ Yivoxi’s successful challenge to Keytruda was the highlight of the 2026 World Lung Cancer Congress. With its data showing an additional 8.2 months of survival, it demonstrates that domestic innovative drugs can not only gain recognition but also succeed in the global market:
- For patients: It offers a more effective treatment, leading to longer survival and better quality of life.
- For the industry: It establishes PD-1/VEGF bispecific antibodies as the new standard for immunotherapy, marking a new era in cancer treatment.
- For the capital market: CanSino Biologics’ value is redefined, and the bispecific antibody track becomes a new investment hotspot, while the dominance of traditional monoclonal antibodies is challenged.
Next, we will closely monitor the international trial results for Yivoxi, as this will be the final step in its quest to become the global “drug king.”